Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (5 ops.)
Latest filing published 07 Jun 2024 for Syros Pharmaceuticals, Inc..
Filing timeline
BuySaleMarsha Fanucci
Insider track record
Disclosed buys
1
Disclosed sells
5
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Marsha Fanucci: trading record in brief
On November 20, 2019, Marsha Fanucci filed a sale of EUR 6,768,952 at Alnylam Pharmaceuticals, Inc., a Nasdaq company. The record counts 5 sales in all, along with one purchase.
The 29 filings, published from June 3, 2016 to June 7, 2024, concern six companies, among them Forma Therapeutics Holdings, Inc. (9 filings), Alnylam (6) and Ironwood Pharmaceuticals Inc (6). Korsana Biosciences, Inc. (4) and Syros Pharmaceuticals, Inc. (3) complete the list; the listed title is Director at each of the 5 companies named. The record includes 13 share grants, 5 option exercises and 5 filings of another kind.
The year 2019 gathers 12 filings, far ahead of 2020 (5) and 2022 (4). Filings appear a median of 2 days after the trade. None falls in the last twelve months. Within 30 days of colleagues at Forma Therapeutics Holdings, Inc., Fanucci has 5, 5 and 5 own market trades, in that order, all in the same direction. Colleagues in order: Mary E. Wadlinger, Paolo Paoletti and Patrick F. Kelly.
Companies and markets linked to Marsha Fanucci
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations29 total
4,000 shares0Common StockSEC:0000950170-24-070711:0
4,000 shares0Common StockSEC:0001209191-23-033723:0
136 shares0Common StockSEC:0001735276-23-000016:0
7,250 sharesCommon StockSEC:0000899243-22-033658:1
52,532 sharesCommon StockSEC:0000899243-22-033658:0
8,000 shares0Common StockSEC:0001209191-22-050554:0
4,500 shares0Common StockSEC:0000899243-22-021660:0
2,750 shares0Common StockSEC:0000899243-21-025091:0
52,532 sharesCommon StockSEC:0000899243-20-017609:0
Canonical exit: 21 Sept 2020 (T+90)
33,781 sharesEnterprise 2 Junior StockSEC:0000899243-20-017609:1
9,847 sharesEnterprise 3 Junior StockSEC:0000899243-20-017609:2
10,240 sharesEnterprise 4 Junior StockSEC:0000899243-20-017609:3
14,026 sharesEnterprise 5 Junior StockSEC:0000899243-20-017609:4
30,000 shares@ US$9.143.2% of flowCommon StockSEC:0001735276-19-000100:0
15,000 shares@ US$9.301.6% of flowCommon StockSEC:0001735276-19-000100:1
15,000 shares@ US$11.332.0% of flowCommon StockSEC:0001735276-19-000100:2
15,000 shares@ US$30.095.3% of flowCommon StockSEC:0001735276-19-000100:3
75,000 shares@ US$100.0087.9% of flowCommon StockSEC:0001735276-19-000100:4
13,671 shares0Common StockSEC:0001209191-19-023507:0
3,279 shares0Common StockSEC:0001209191-19-023507:1
4,056 sharesClass A Common StockSEC:0001209191-19-023411:0
13,671 shares0Common StockSEC:0001209191-19-023565:0
3,279 shares0Common StockSEC:0001209191-19-023565:1
44,863 sharesClass B Common StockSEC:0001209191-19-001491:0
44,863 sharesClass A Common StockSEC:0001209191-19-001491:1
25 of 29 declarations
